The Non-Consensus
Latest Articles
Mylan's Issues Persist But Expectations Are Low And Several Catalysts Are Coming
Pharma Remains The Key Debate For Johnson & Johnson, But Other Segments Showing Signs Of A Recovery
Abbott: MitraClip Success Provides Upside For Stock
Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron
MITRA-FR Potentially Not As Negative As It Appears For Upcoming COAPT Results For Abbott
Amgen's Aimovig Launch Looks Strong; Monitor Biosimilar Developments
Will Revlimid's Patent Protection Hold Up For Celgene?
How Big Is The Biosimilar Threat To AbbVie's Humira?
What BP's Oil Spill Tells Us About Potential SEC Enforcement For Tesla
Gilead Debate Focused On Threat Of GSK In HIV And On Management Departures
Catalyst-Rich Months Ahead For The Alkermes Pipeline
Diabetes And Upcoming REWIND Data Key Topics Of Debate For Eli Lilly
Will Facebook's Dating Feature Crush Match, Or Does It Present A Buying Opportunity?
Street Bullish On Reata's Chronic Kidney Disease Implications And Rejection Of Hyperfiltration Argument
Allergan: Inflammation Is The Reason Investors Did Not React Well To Abicipar Results
A Deep Dive Into The Promising Results Of Biogen's BAN2401 And Other Alzheimer's Treatments
Allergan: Crucial Period Ahead For Company As Activist Pressure Mounts
Can Pfizer Grow To Targets With LOE Headwinds Ahead?
Teva: Investors Split On Outlook; Near-Term Outlook Not As Bad But Longer-Term Concerns Remain
Diabetes Growth Key To Hitting Medtronic's Longer-Term Targets
Will Johnson & Johnson's Pipeline Drugs Offset Sales Erosion To Upcoming Generics?
Etsy Finally Raises Fees; Multiple Levers Remain For Higher Growth
With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis
Amazon's Next Leg Of Growth Could Come From High-Margin Categories
Guidance Concerns Grow As Mylan's Drug Approvals Are Delayed
Select Comfort's New Mattresses Could Provide A Boost To Sales
Medtronic's Diabetes Segment Generating Excitement
How Much Will Facebook Advertising Slow In Second Half 2017?
Be Careful Of The Free Cash Flow Defense For Bed Bath & Beyond
Word On Wall Street: Can Lululemon Return To Its Former Glory?
Word On Wall Street: Activision Blizzard Gaming Is Worth Watching
Word On Wall Street: A Closer Look At Chipotle's Q1 Results